Effects of Estrogen, an ERα Agonist and Raloxifene on Pressure Overload Induced Cardiac Hypertrophy

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Westphal, Christina ^a,b   Schubert, Carola ^a,b   Prelle, Katja ^c   Penkalla, Adam ^d   Fliegner, Daniela ^a,b   Petrov, George ^d   Regitz Zagrosek, Vera ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c BAYER PHARMA AG   (Germany)

^d DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA LE2; CARDIOVASCULAR AGENT; CONNECTIVE TISSUE GROWTH FACTOR; ESTRADIOL; PLACEBO; RALOXIFENE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; CTGF GENE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HEART EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE OVERLOAD; HEART VENTRICLE PRESSURE; MOUSE; NONHUMAN; OVARIECTOMY; SURVIVAL RATE; SYSTOLIC DYSFUNCTION; TGFBETA GENE;

ANIMALS; AORTA; BIOLOGICAL MARKERS; CARDIOMEGALY; CONSTRICTION, PATHOLOGIC; DISEASE PROGRESSION; ESTROGEN RECEPTOR ALPHA; ESTROGENS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FIBROSIS; GENE EXPRESSION REGULATION; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; ORGAN SIZE; PRESSURE; RALOXIFENE; SURVIVAL ANALYSIS; SYSTOLE; UTERUS; VENTRICULAR FUNCTION, LEFT;

ANIMALIA; MUS;

EID: 84870804619     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050802     Document Type: Article

References (38)

1. Sadoshima J, Izumo S, (1997) The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 59: 551-571.
2. Carroll JD, Carroll EP, Feldman T, Ward DM, Lang RM, et al. (1992) Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation 86: 1099-1107.
3. Frey N, Olson EN, (2003) Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65: 45-79.
4. Weber KT, Sun Y, Tyagi SC, Cleutjens JP, (1994) Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 26: 279-292.
5. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, et al. (2002) Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347: 1397-1402.
6. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, et al. (2003) The EuroHeart Failure survey programme- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 24: 442-463.
7. Regitz-Zagrosek V, (2006) Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov 5: 425-438.
8. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK, (1996) The progression from hypertension to congestive heart failure. Jama 275: 1557-1562.
9. Tamura T, Said S, Gerdes AM, (1999) Gender-related differences in myocyte remodeling in progression to heart failure. Hypertension 33: 676-680.
10. Petrov G, Regitz-Zagrosek V, Lehmkuhl E, Krabatsch T, Dunkel A, et al. (2010) Regression of myocardial hypertrophy after aortic valve replacement: faster in women? Circulation 122: S23-28.
11. Villar AV, Cobo M, Llano M, Montalvo C, Gonzalez-Vilchez F, et al. (2009) Plasma levels of transforming growth factor-beta1 reflect left ventricular remodeling in aortic stenosis. PLoS One 4: e8476.
12. Gardner JD, Brower GL, Voloshenyuk TG, Janicki JS, (2008) Cardioprotection in female rats subjected to chronic volume overload: synergistic interaction of estrogen and phytoestrogens. Am J Physiol Heart Circ Physiol 294: H198-204.
13. van Eickels M, Patten RD, Aronovitz MJ, Alsheikh-Ali A, Gostyla K, et al. (2003) 17-beta-estradiol increases cardiac remodeling and mortality in mice with myocardial infarction. J Am Coll Cardiol 41: 2084-2092.
14. van Eickels M, Grohe C, Cleutjens JP, Janssen BJ, Wellens HJ, et al. (2001) 17beta-estradiol attenuates the development of pressure-overload hypertrophy. Circulation 104: 1419-1423.
15. Donaldson C, Eder S, Baker C, Aronovitz MJ, Weiss AD, et al. (2009) Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation. Circ Res 104: 265-275, 211p following 275.
16. Iwakura A, Shastry S, Luedemann C, Hamada H, Kawamoto A, et al. (2006) Estradiol enhances recovery after myocardial infarction by augmenting incorporation of bone marrow-derived endothelial progenitor cells into sites of ischemia-induced neovascularization via endothelial nitric oxide synthase-mediated activation of matrix metalloproteinase-9. Circulation 113: 1605-1614.
17. Mendelsohn ME, Karas RH, (1994) Estrogen and the blood vessel wall. Curr Opin Cardiol 9: 619-626.
18. Wingrove CS, Garr E, Godsland IF, Stevenson JC, (1998) 17beta-oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta 1406: 169-174.
19. Mahmoodzadeh S, Dworatzek E, Fritschka S, Pham TH, Regitz-Zagrosek V, (2010) 17beta-Estradiol inhibits matrix metalloproteinase-2 transcription via MAP kinase in fibroblasts. Cardiovasc Res 85: 719-728.
20. Patten RD, Pourati I, Aronovitz MJ, Alsheikh-Ali A, Eder S, et al. (2008) 17 Beta-estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myocardial infarction and pressure overload. J Card Fail 14: 245-253.
21. Hulley S, Grady D, Bush T, Furberg C, Herrington D, et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Jama 280: 605-613.
22. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Jama 288: 321-333.
23. Skavdahl M, Steenbergen C, Clark J, Myers P, Demianenko T, et al. (2005) Estrogen receptor-beta mediates male-female differences in the development of pressure overload hypertrophy. Am J Physiol Heart Circ Physiol 288: H469-476.
24. Arias-Loza PA, Hu K, Dienesch C, Mehlich AM, Konig S, et al. (2007) Both estrogen receptor subtypes, alpha and beta, attenuate cardiovascular remodeling in aldosterone salt-treated rats. Hypertension 50: 432-438.
25. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, et al. (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139: 4252-4263.
26. Ogita H, Node K, Liao Y, Ishikura F, Beppu S, et al. (2004) Raloxifene prevents cardiac hypertrophy and dysfunction in pressure-overloaded mice. Hypertension 43: 237-242.
27. Babiker FA, Lips D, Meyer R, Delvaux E, Zandberg P, et al. (2006) Estrogen receptor beta protects the murine heart against left ventricular hypertrophy. Arterioscler Thromb Vasc Biol 26: 1524-1530.
28. Backhaus K, Erichson B, Plinke W, Weiber R, (2008) Multivariate Analysemethoden. Springer Verlag 12: 323-386.
29. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, et al. (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. Jama 287: 847-857.
30. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, et al. (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355: 125-137.
31. Fliegner D, Schubert C, Penkalla A, Witt H, Kararigas G, et al. (2010) Female sex and estrogen receptor-beta attenuate cardiac remodeling and apoptosis in pressure overload. Am J Physiol Regul Integr Comp Physiol 298: R1597-1606.
32. Pelzer T, Jazbutyte V, Hu K, Segerer S, Nahrendorf M, et al. (2005) The estrogen receptor-alpha agonist 16alpha-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats. Cardiovasc Res 67: 604-612.
33. Xu Y, Arenas IA, Armstrong SJ, Davidge ST, (2003) Estrogen modulation of left ventricular remodeling in the aged heart. Cardiovasc Res 57: 388-394.
34. Pedram A, Razandi M, Lubahn D, Liu J, Vannan M, et al. (2008) Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-beta to inhibit calcineurin. Endocrinology 149: 3361-3369.
35. Leask A, Holmes A, Black CM, Abraham DJ, (2003) Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem 278: 13008-13015.
36. Dean RG, Balding LC, Candido R, Burns WC, Cao Z, et al. (2005) Connective tissue growth factor and cardiac fibrosis after myocardial infarction. J Histochem Cytochem 53: 1245-1256.
37. Babiker FA, Lips DJ, Delvaux E, Zandberg P, Janssen BJ, et al. (2007) Oestrogen modulates cardiac ischaemic remodelling through oestrogen receptor-specific mechanisms. Acta Physiol (Oxf) 189: 23-31.
38. Bender R, Lange S, Ziegler A, (2007) [common significance tests]. Dtsch Med Wochenschr 132: e24-25.